GLP-1 & Incretins News

Every article we’ve published on GLP-1 & Incretins, newest first — 1 in total. Each one is sourced to primary regulatory, trial, or peer-reviewed documents and links back to the original.

Detailed view of a semaglutide injection pen, commonly used for diabetes treatment, on a plain background. — Weekly injection pen beside a paper calendar used to record daily alcohol consumption

August 6, 2026

Semaglutide Alcohol Use Disorder Trial Enrolls 622 Veterans

The largest test yet of a GLP-1 receptor agonist for drinking has opened enrollment: a VA-sponsored semaglutide alcohol use disorder trial seeking 622 participants. It follows a smaller federally funded phase 2 study and observational reports on smoking and mood in another patient population.

SemaglutideGLP-1 & Incretins

How this page is made. PeptideWiz News covers regulatory actions, published research, and industry developments from a fixed list of primary sources — the FDA, NIH, EMA, ClinicalTrials.gov, PubMed, peer-reviewed journals, and company press rooms. Articles are drafted with AI assistance from those sources, reviewed before publication, and always link to the original. Read the full editorial standards & corrections policy. This is journalism about peptides, not medical advice: it does not recommend any substance, does not state dosages, and is not a substitute for your provider.

← Back to all peptide news